"Health · Crisis" — OpenWatch Search

HealthCrisis🇺🇸United States46d ago

WASHINGTON — <a class="Link" href="https://apnews.com/hub/us-supreme-court" target="_blank" >The Supreme Court</a> on Thursday preserved women’s access to <a class="Link" href="https://apnews.com/article/mifepristone-abortion-pill-makary-22576dbfafca1afe0146ee496540c9a4" target="_blank" >a drug used in the most common method of abortion</a>, rejecting <a class="Link" href="https://apnews.com/article/abortion-pills-mail-louisiana-ruling-40d60a9bf6212480e527480757b603c3" target="_blank" >lower-court restrictions</a> while a lawsuit continues.The court’s order allows women seeking abortions to continue obtaining the drug, mifepristone, at pharmacies or through the mail, without an in-person visit to a doctor. Access is likely to remain uninterrupted at least into next year as the case plays out, including a potential appeal to the high court.The justices granted emergency requests from makers of mifepristone, who are appealing a federal appeals court ruling that would require women to see a doctor in person and halt delivery of mifepristone through the mail. The federal Food and Drug Administration, which first approved mifepristone for use in abortion in 2000, stopped requiring in-person visits five years ago.Justices Clarence Thomas and Samuel Alito dissented, with Thomas writing that the two companies, Danco Laboratories and GenBioPro, are not entitled to the court's action to spare them “lost profits from their criminal enterprise.”Anti-abortion groups, frustrated with President Donald Trump’s administration, are pushing the FDA to move faster with a review that they hope will result in restrictions on mifepristone, including blocking it from being prescribed via telehealth platforms.

4.7/10·Chicago Sun-Times

Primary Source ↗Details →